Showing 2531-2540 of 5833 results for "".
- Vehicles, Infectious Disease, and Acne Updates from Day 2 at DERM2019https://practicaldermatology.com/news/vehicles-infectious-disease-and-acne-updates-from-day-2-at-derm2019/2460099/The DERM2019 NP/PA CME Conference continued to delight audiences with esteemed faculty presenters, including those who presented Friday, including April Armstrong, David Cohen, Kara Gooding, Joseph Gorelick, Julie Harper, Jayme Heim, George Keough, Leon Kircik, Kristine Kucera, Gilly Munavalli, T
- Psoriasis, Psoriatic Arthritis, and AD Updates from Day 1 at DERM2019https://practicaldermatology.com/news/psoriasis-psoriatic-arthritis-and-ad-updates-from-day-1-at-derm2019/2460098/The first day of the DERM2019 NP/PA CME Conference kicked off with a bang! Exciting talks and lively panel discussions from April Armstrong, David Cohen, Adam Friedman, Kara Gooding, and Joe Gorelick were the mainstay of the day. Psoriasis Pathogenesis and Treatment T
- Baylor Dermatologist Offers Anti-Aging Advice in Response to FaceApp Crazehttps://practicaldermatology.com/news/baylor-dermatologist-offers-anti-aging-advice-in-response-to-faceapp-craze/2460097/The FaceApp is taking social media by storm as celebrities and social media users across the nation morph their faces to look decades older. While it is currently being used for comedic purposes, you may have patients asking how to keep the app from turning into reality. Rajani Katta, M
- Novartis Offers Free Genetic Testing for Advanced Melanomahttps://practicaldermatology.com/news/novartis-offers-free-genetic-testing-for-advanced-melanoma/2460095/The Know Now Testing Program is an initiative from Novartis in collaboration with Quest Diagnostics that offers genetic mutation testing at no cost for all patients with stage III or stage IV melanoma. Nearly half of all advanced melanoma patients carry a specific mutation, called BRAF.
- Positive Results Seen in Phase 3 FMX101 Acne Studyhttps://practicaldermatology.com/news/study-positive-results-see-in-phase-3-fmx101-acne-study/2460088/In patients with moderate to severe acne vulgaris, treatment with FMX101 4% topical minocycline foam is well tolerated and effective for reducing the number of inflammatory lesions, according to results of a randomized trial published in the Journal of the American Academy of Dermatology
- Meet truSculpt flex: Cutera’s Solution for Toned Abs, Butts and Thighshttps://practicaldermatology.com/news/meet-trusculpt-flex-cuteras-solution-for-toned-abs-butts-and-thighs/2460084/Cutera is launching the new truSculpt flex, muscle sculpting platform in the United States, and commercial shipments are slated to begin immediately. truSculpt flex is FDA-cleared for the indications of the improvement of abdominal tone, strengt
- Hair Loss Breakthrough: 3D-Printing Creates “Hair Farms”https://practicaldermatology.com/news/hair-loss-breakthrough-research-uses-3d-printing-to-create-hair-farms/2460083/Columbia researchers have created a way to use 3-D printing to create “hair farms” in a dish, which could open up hair restoration surgery to more people, including women, and improve the way pharmaceutical companies search for new hair growth drugs. The findings, which appe
- Dominion Aesthetic Technologies, Inc.’s eon FR Scores FDA Nodhttps://practicaldermatology.com/news/dominion-aesthetic-technologies-incs-eon-fr-scores-fda-nod/2460077/The FDA has cleared Dominion Aesthetic Technologies, Inc
- FDA Clears Allergan's CoolTone Devicehttps://practicaldermatology.com/news/fda-clears-allergans-cooltone-device/2460075/The FDA has cleared Allergan plc's CoolTone device for improvement of abdominal tone, strengthening of the abdominal muscles, and development for firmer abdomen. CoolTone is also indicated for strengthening, toning and firming of buttocks and thighs. “By partnering with A
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s en